Mark Mallon Chief Executive Officer and Board Member
Mr. Mallon was appointed to be the NeoGenomics Chief Executive Officer and Member of the Board of Directors, effective April 15, 2021. Mark Mallon has had a long and distinguished career in health care. Prior to serving as CEO of Ironwood Pharmaceuticals, where he led the financial transformation of the company to profitability and significantly accelerated the growth of its commercial product, Mr. Mallon spent twenty-four years at AstraZeneca, where he had a strong track record of success building industry-leading businesses in the U.S. and globally. Mr. Mallon served on the executive committee as Executive Vice President of Global Product and Portfolio Strategy, leading global marketing, pricing and market access, medical affairs (including health economics and real-world evidence), and corporate affairs. He also co-chaired the Late-Stage Product Development Committee for AstraZeneca’s $18 billion Bio-Pharmaceutical business, and, prior to that role, led AstraZeneca’s International Region, where he managed a high-growth $6.5 billion business with over 20,000 employees. He launched AstraZeneca’s emerging market strategy and led the expansion and growth of the Company’s business in China, where it was the second-fastest growing major multinational and second-largest pharmaceutical company. As EVP of International, he also oversaw $800 million of Oncology sales spanning more than 50 countries. As President of AstraZeneca China, Chief Operating Officer of AstraZeneca Japan, Vice President of U.S. Sales and Marketing Operations and President of AstraZeneca Italy, Mr. Mallon delivered several best-in-class new product launches, including immunotherapy and targeted therapeutics. Mr. Mallon holds a B.S. in Chemical Engineering from the University of Pennsylvania and an M.B.A. in Marketing and Finance from the Wharton School of Business.
Ms. McKenzie joined NeoGenomics in 2017 and has recently served as our Vice President of Finance and Chief Accounting Officer. For the past six months, Kathryn has assumed a key finance leadership role at our company. Before joining NeoGenomics, Ms. McKenzie served in various roles at Chico's FAS, including Assistant Controller and Director of Financial Reporting and Treasury, and at Ernst and Young. Ms. McKenzie is a Certified Public Accountant and holds a Master's of Science in Accountancy from the University of North Carolina Wilmington.
Mr. Shovlin joined NeoGenomics in 2014 as the Chief Operating Officer, and now serves as the President, Clinical Services Division. Previously, he served as Chief Development Officer for Bostwick Laboratories, a leading provider of anatomic pathology testing services. From 2005 to 2011, he served in several positions of increasing responsibility, ultimately as President and Chief Executive Officer for Aureon Biosciences, Inc., a venture-backed diagnostics company focused on developing novel and proprietary prostate cancer tests. Mr. Shovlin also served as Executive Director of Anatomic Pathology and as Director of Managed Care for Quest Diagnostics from 2003 until 2005, and held sales leadership positions at Dianon Systems from 1997 until 2003. Mr. Shovlin served as a Captain, Infantry Officer, in the United States Marine Corps from 1992 until 1997 where he served as a Platoon Commander and Company Commander with 1st Battalion 4th Marines and as an Instructor and Staff Platoon Commander at The Basic School. He received his bachelor's degree from Pennsylvania State University, and his MBA in Finance from Rutgers University.
George A. Cardoza
President and Chief Operating Officer, Lab Operations
George A. Cardoza President and Chief Operating Officer, Lab Operations
George Cardoza began his career with NeoGenomics in 2009, serving as the company’s Chief Financial Officer until his appointment to President of Pharma Services in 2018. Prior to NeoGenomics, Prior to that, he was the Chief Financial Officer at Protocol Integrated Direct Marketing. Mr. Cardoza spent fifteen years with Quest Diagnostics, including years when it was still part of Corning Inc. With Corning Inc. he worked with the Corning Life Sciences Division, which did several acquisitions in the Pharma services space. These acquisitions formed the pieces of Covance, which Corning spun out at the same time as Quest in 1996. Mr. Cardoza received his Bachelor’s Degree in Finance and Accounting from Syracuse University and his M.B.A. from Michigan State University.
Dr. Gina Wallar started her career with NeoGenomics in 2014 as Director, Scientific Affairs and Project Management, having previously served as the Director for LabCorp Clinical Trials for over 12 years. From 2016 to 2018 she was VP for Sales and Project Management for Pharma Services and most recently served as our Senior Vice President, Clinical Division. Dr. Wallar received her MPH in Epidemiology and Biostatistics from Boston University and received her PhD at UCLA in cancer epidemiology.
Mr. Bonello most recently served as our Chief Strategy and Corporate Development Officer helping to formulate the company's growth strategy. Bill also recently served as Director of Investor Relations. Prior to joining NeoGenomics, Bill worked as a healthcare equity analyst covering diagnostic services and product stocks at Craig-Hallum and at a variety of firms, and was also Senior Vice President for Investor Relations at LabCorp. Mr. Bonello received his B.A. degree from Carleton College and his MBA from the Kellogg School of Management at Northwestern University.
Clive Morris is President at Inivata. Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ.
He has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. Most recently Clive founded and lead Health Innovation Manchester, to develop an innovation ecosystem involving the decentralization of £6bn per annum of health and social care services. He is also a non-executive director of Wheatsheaf investments.
Clive is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, has an Executive MBA and trained as a physician at the University of Manchester.
Mrs. Balliet joined NeoGenomics in 2008 as Director, Human Resources. Since then, she has been appointed as Vice President, Human Resources in 2015 and Chief Culture Officer in 2016. Mrs. Balliet has managed Human Resources as the Company grew from 100 employees to more than 900 employees. She is responsible for all areas of Human Resources, including recruiting, training, compensation, incentive plans, and organizational development. Mrs. Balliet received her Bachelor of Science degree in Psychology and her Master of Science degree in Business Management from the University of Florida.
John Mooney was named NeoGenomics’ Chief Technology Officer in 2021.
Prior to joining the company, John held several roles of increasing responsibility at BioReference Laboratories and served as their Chief Information Officer from 2016 – 2021. During his tenure at BioReference, the company revenues grew from $422M to greater than $1.4B.
Earlier in his career, John worked for several software companies and was the founding architect for two successful digital health startups. He is a subject matter expert in healthcare interoperability, having shaped standards for HL7 and ONC.
John holds a B.S. in Operations & Information Management from the University of Scranton.
Stephanie has over 13 years' experience developing and overseeing programs to ensure compliance with various global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining the Company, Stephanie managed global compliance operations for and was the Compliance Officer for the Americas Region at Varian Medical Systems Inc. from 2015 to 2017, with a focus on global anti-corruption and ethical compliance requirements. Prior to Varian, she was the Compliance and Privacy Officer for Myriad Genetic Laboratories, where she implemented and provided oversight for programs supporting compliance with the Anti-kickback Statute, Stark Law, the Food and Drug Administration, billing and reimbursement, research, and global data privacy and protection requirements from 2010 to 2015. Stephanie also has a wealth of compliance experience in large health systems, behavioral health, and has served as an internal auditor. She has a Bachelor of Science in Healthcare Administration from Northern Illinois University and is a Certified Healthcare Professional (CHP), Certified in Healthcare Privacy (CHP), and a Certified Internal Auditor (CIA).
Douglas Brown Chief Strategy and Corporate Development Officer
Prior to joining NeoGenomics, Mr. Brown was Senior Managing Director with SVB Leerink with significant expertise in the oncology diagnostic sector. During his career, he has advised clients in over 100 successful M&A and Corporate Financing transactions. Doug advised General Electric on the sale of Clarient, and recently advised NeoGenomics on the acquisition of Genoptix and the oncology assets of Human Longevity. Mr. Brown earned his MBA from the Fuqua School of Business at Duke University and received his undergraduate business degree from the University of Texas at Austin.
Mr. Silva has over 17 years of sales, marketing and general management experience in healthcare delivery, medical devices and diagnostics, and pharmaceuticals. Mr. Silva joined NeoGenomics in June 2020 as the Chief Marketing Officer, after leading Precision Medicine efforts at Novartis resulting in the the successful 2019 launch of PIQRAY (alpelisib) and 2020 launch of TABRECTA (capmatinib).
Prior to Novartis, Mr. Silva was with Becton Dickinson (BD) where he first led global strategic marketing excellence for their $1B global injection business and later was appointed head of Marketing and Analytics for their $700M US Diabetes Care business. Prior to BD, Mr. Silva was with Johnson & Johnson’s Ortho-Clinical Diagnostics franchise, where he held various leadership roles within Global Marketing, Strategic Marketing and Regional Marketing, including multiple product and campaign launches. Prior to this, Mr. Silva started his own healthcare company based in Southern California that focused on senior care, which he ran for almost 10 years and grew to over 100 employees. Additionally, Mr. Silva began his career as a practicing California plaintiff’s attorney, litigating employment law cases in Southern California.
Mr. Silva earned his BA from Rutgers University, his JD from California Western School of Law, and his MBA from Rutgers Business School, with a focus on Marketing and Pharmaceutical Management.
Steven G. Brodie, Ph.D.
Vice President of Worldwide Pharma Services Operations
Steven G. Brodie, Ph.D. Vice President of Worldwide Pharma Services Operations
Dr. Brodie is the Vice President of Operations at NeoGenomics. Previously, he served as the company's President of the Pharma Services division, Chief Scientific Officer and Director of BioPharma Operations, Florida Laboratory Director, and Director of Molecular and Cytogenetics. Prior to joining NeoGenomics, Dr. Brodie served as Senior Director of Cytogenetics, Assistant Director of Molecular Genetics, and Scientific Director of Maternal Serum Screening at Specialty Laboratories/Quest Diagnostics in Valencia, CA. Dr. Brodie trained pathology residents in genetic testing at both Loma Linda University Medical Center, where he served as the Affiliate Rotation Director, and University of Southern California, Keck School of Medicine, where he served as a Clinical Assistant Professor of Pathology. Prior to joining Quest Diagnostics, he held a variety of research and clinical positions at the National Institutes of Health, University of New Mexico School of Medicine, and UCLA David Geffen School of Medicine. Dr. Brodie received his genetics training at the UCLA/Cedar-Sinai Medical Center medical genetics training program in Los Angeles, CA. He received his Ph.D. from UNM School of Medicine and completed Clinical Genetics training in Cytogenetics and Molecular Genetics at UCLA. Dr. Brodie is Board Certified by the American Board of Medical Genetics in these specialties and holds Director licenses in Florida, California, and New York. Throughout his career, Dr. Brodie has held various research and clinical positions at the NIH, UNM and UCLA, and comes to us after directing high throughput testing in Cytogenetics, FISH, Molecular Genetics, and Oncology for Quest Diagnostics, Nichols Institute.